Trial Profile
Temodal (TMZ) [temozolomide] in Concomitant Radiochemotherapy Followed by Sequential TMZ Chemotherapy in Newly Diagnosed Glioblastoma Multiforme Patients - an Observational Program
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 17 Nov 2010 Actual initiation date changed from May 2007 to Apr 2007 as reported by ClinicalTrials.gov.
- 29 Jan 2010 Actual end date (April 2009) added as reported by ClinicalTrials.gov.
- 29 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.